Poor
Needs Revision
Patient Risk:
Medium
Summary
The response includes multiple claims about bleeding risk, aspirin/anticoagulant/antiplatelet interactions, symptom-based bleeding signs, kidney/dehydration guidance, and acetaminophen comparisons that are not supported by the provided FDA label excerpts. The included boxed-warning GI and CV risk statements for NSAIDs/ibuprofen are directionally consistent, but many additional assertions are unsupported relative to the supplied prescribing information.
Category Scores
Accurate Statements
Nonsteroidal anti-inflammatory drugs (NSAIDs) including ibuprofen cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation.
Boxed Warning (Gastrointestinal Risk) and Section 5.2 (Gastrointestinal Bleeding, Ulceration, and Perforation) state NSAIDs including ibuprofen cause increased risk of serious GI adverse events including bleeding, ulceration, and perforation.
NSAIDs cause increased risk of serious cardiovascular thrombotic events including myocardial infarction and stroke.
Boxed Warning (Cardiovascular Thrombotic Events) and Section 5.1 state NSAIDs cause increased risk of serious cardiovascular thrombotic events including MI and stroke.
The risk of NSAID-associated GI adverse events can occur at any time during use, including without warning symptoms; short-term therapy is not without risk.
Boxed Warning (Gastrointestinal Risk) and Section 5.2 state events can occur at any time and without warning symptoms; even short-term therapy is not without risk.
The concurrent use of aspirin and an NSAID such as ibuprofen increases the risk of serious gastrointestinal events.
Section 5.1 states concurrent use of aspirin and an NSAID, such as ibuprofen, increases the risk of serious GI events.
Unsupported Statements
Many “blood thinners” (anticoagulants and antiplatelet medicines) increase bleeding risk.
Not supported by the provided label excerpts (which focus on NSAID risks and include concomitant anticoagulants as GI bleeding risk factors, but do not provide a general statement about 'many blood thinners' increasing bleeding risk).
Ibuprofen can add to bleeding risk mainly by irritating the stomach.
The excerpts do not attribute bleeding risk specifically to 'irritating the stomach.'
Ibuprofen can affect platelet function.
No platelet-function claim is supported by the provided excerpts.
Adding ibuprofen to anticoagulants can raise the chance of bleeding.
The excerpts mention concomitant use of anticoagulants as a risk factor for GI bleeding, but do not provide the specific 'adding ibuprofen to anticoagulants' statement about bleeding chance (outside the GI risk-context).
Adding ibuprofen to antiplatelet drugs (including clopidogrel and aspirin) may further increase bleeding risk.
Section 5.1 excerpt only explicitly mentions aspirin with NSAIDs increasing serious GI events; the provided excerpts do not mention clopidogrel or a general 'bleeding risk' framing for antiplatelet drugs.
The risk of the combination depends on the specific blood thinner.
Not supported by the provided excerpts.
Anticoagulants include warfarin, apixaban, rivaroxaban, and dabigatran.
No such drug list is provided in the supplied label excerpts.
Antiplatelet drugs include clopidogrel and aspirin.
No such drug list is provided in the supplied label excerpts.
The main concerns of the combination are increased bleeding risk overall, especially gastrointestinal bleeding.
The excerpts support increased serious GI adverse events with NSAID use and note risk factors, but do not support the broader 'main concerns of the combination' wording.
NSAIDs like ibuprofen may have an added effect on platelets and cause stomach lining injury.
Platelet effects and 'stomach lining injury' are not supported by the provided excerpts.
Acetaminophen (paracetamol) is often the preferred first-choice option for pain or fever for many people on blood thinners.
No acetaminophen comparative or 'preferred first-choice' guidance is included in the provided label excerpts.
Acetaminophen does not work the same way as ibuprofen.
Mechanism comparison is not present in the provided excerpts.
Acetaminophen is less likely to increase bleeding risk than ibuprofen.
Not supported by the provided excerpts.
Dose limits for acetaminophen should follow clinician guidance and the product label.
Not present in the provided excerpts.
Black, tarry stools can be a sign of bleeding. Vomiting blood can be a sign of bleeding. Unusual bruising can be a sign of bleeding. Nosebleeds that do not stop can be a sign of bleeding. Bleeding gums can be a sign of bleeding. Severe or persistent headache can be a sign of bleeding. Dizziness can be a sign of bleeding. Weakness can be a sign of bleeding. A fall or head injury is especially important when taking anticoagulants.
None of these specific symptom-based warnings are included in the provided label excerpts.
Ibuprofen should be avoided and a clinician contacted if there is a history of stomach ulcers or gastrointestinal bleeding.
The excerpts mention risk factors including prior history of peptic ulcer disease and/or GI bleeding increasing risk, but do not instruct to 'avoid' ibuprofen or contact a clinician in this manner.
Ibuprofen should be avoided and a clinician contacted if there is kidney disease or dehydration. Ibuprofen can worsen kidney function.
Kidney disease/dehydration guidance and kidney function worsening are not present in the provided excerpts.
Ibuprofen should be avoided and a clinician contacted if a clinician tells the patient to avoid NSAIDs for any reason.
Not supported by the provided excerpts.
Ibuprofen should be avoided and a clinician contacted if the patient is unsure whether medication is an anticoagulant or antiplatelet.
Not supported by the provided excerpts.
One dose of ibuprofen often doesn’t cause problems.
Section 5.2 states even short-term therapy is not without risk; the 'often doesn’t cause problems' claim is not supported.
Whether a dose causes problems depends on the specific blood thinner, dose, timing, and bleeding risk.
Not supported by the provided excerpts.
Short-term, single-dose or limited use of ibuprofen may be allowed by some clinicians in low-risk patients. With higher-risk anticoagulants/antiplatelets or other risk factors (age, ulcers, prior bleeding), avoidance is more common.
The provided excerpts do not include these conditional clinical-allowance/avoidance statements.
Contradictions
Low
AI Statement
One dose of ibuprofen often doesn’t cause problems.
Label Reference
Boxed Warning (Gastrointestinal Risk) and Section 5.2 state serious GI events can occur at any time during use and even short-term therapy is not without risk.
Important Omissions
CABG-surgery contraindication is not mentioned by the response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The response contains several unsupported safety claims (e.g., acetaminophen comparisons, symptom lists, kidney-dehydration guidance) that could mislead decision-making. While it correctly reflects that NSAIDs/ibuprofen increase GI risk and can increase CV thrombotic risk, the lack of key contraindication context (CABG) and the unsupported conditional/avoidance guidance increase the chance of inaccurate risk interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Multiple statements about bleeding signs, comparative acetaminophen safety, platelet effects, kidney/dehydration precautions, and clinician-avoidance/allowance guidance are not supported by the provided label excerpts; CABG contraindication is omitted.
Suggested Improvement
Limit claims to what is supported by the provided excerpts (NSAID/ibuprofen increased serious CV thrombotic risk; increased serious GI adverse events including bleeding/ulceration/perforation and timing; aspirin+NSAID increases serious GI events; risk factors for GI bleeding include prior peptic ulcer/GI bleeding and concomitant anticoagulants/aspirin/corticosteroids/SSRIs; include the CABG surgery contraindication). Remove or rephrase unsupported symptom and comparative acetaminophen statements.